These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36562218)

  • 1. Shine, Shine, Ruthenium Caged Drug.
    Etchenique R; Filevich O
    Photochem Photobiol; 2023 Mar; 99(2):860-862. PubMed ID: 36562218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Lock-and-Kill Anticancer Photoactivated Chemotherapy Agent
    van Geest EP; Götzfried SK; Klein DM; Salitra N; Popal S; Husiev Y; Van der Griend CJ; Zhou X; Siegler MA; Schneider GF; Bonnet S
    Photochem Photobiol; 2023 Mar; 99(2):777-786. PubMed ID: 36315051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To cage or to be caged? The cytotoxic species in ruthenium-based photoactivated chemotherapy is not always the metal.
    Cuello-Garibo JA; Meijer MS; Bonnet S
    Chem Commun (Camb); 2017 Jun; 53(50):6768-6771. PubMed ID: 28597879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy.
    Lu Y; Zhu D; Le Q; Wang Y; Wang W
    Nanoscale; 2022 Nov; 14(44):16339-16375. PubMed ID: 36341705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photosubstitution in a trisheteroleptic ruthenium complex inhibits conjunctival melanoma growth in a zebrafish orthotopic xenograft model.
    Chen Q; Cuello-Garibo JA; Bretin L; Zhang L; Ramu V; Aydar Y; Batsiun Y; Bronkhorst S; Husiev Y; Beztsinna N; Chen L; Zhou XQ; Schmidt C; Ott I; Jager MJ; Brouwer AM; Snaar-Jagalska BE; Bonnet S
    Chem Sci; 2022 Jun; 13(23):6899-6919. PubMed ID: 35774173
    [No Abstract]   [Full Text] [Related]  

  • 6. Light-activated ruthenium (II)-bicalutamide prodrugs for prostate cancer.
    Zhao J; Liu N; Sun S; Gou S; Wang X; Wang Z; Li X; Zhang W
    J Inorg Biochem; 2019 Jul; 196():110684. PubMed ID: 31054419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lightening up Ruthenium Complexes to Fight Cancer?
    Mari C; Gasser G
    Chimia (Aarau); 2015; 69(4):176-81. PubMed ID: 26668934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photo-induced DNA cleavage and cytotoxicity of a ruthenium(II) arene anticancer complex.
    Brabec V; Pracharova J; Stepankova J; Sadler PJ; Kasparkova J
    J Inorg Biochem; 2016 Jul; 160():149-55. PubMed ID: 26778426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
    Bergamo A; Sava G
    Dalton Trans; 2011 Aug; 40(31):7817-23. PubMed ID: 21629963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Red-Light-Activated Ruthenium-Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells.
    Lameijer LN; Ernst D; Hopkins SL; Meijer MS; Askes SHC; Le Dévédec SE; Bonnet S
    Angew Chem Int Ed Engl; 2017 Sep; 56(38):11549-11553. PubMed ID: 28666065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Red-Light-Responsive Metallopolymer Nanocarriers with Conjugated and Encapsulated Drugs for Phototherapy Against Multidrug-Resistant Tumors.
    Chen M; Gong N; Sun W; Han J; Liu Y; Zhang S; Zheng A; Butt HJ; Liang XJ; Wu S
    Small; 2022 Jul; 18(27):e2201672. PubMed ID: 35665442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nuclear permeable Ru(ii)-based photoactivated chemotherapeutic agent towards a series of cancer cells: in vitro and in vivo studies.
    Tian N; Feng Y; Sun W; Lu J; Lu S; Yao Y; Li C; Wang X; Zhou Q
    Dalton Trans; 2019 May; 48(19):6492-6500. PubMed ID: 30994660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates.
    Renfrew AK; Karges J; Scopelliti R; Bobbink FD; Nowak-Sliwinska P; Gasser G; Dyson PJ
    Chembiochem; 2019 Nov; 20(22):2876-2882. PubMed ID: 31102568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Near-infrared light photocontrolled targeting, bioimaging, and chemotherapy with caged upconversion nanoparticles in vitro and in vivo.
    Chien YH; Chou YL; Wang SW; Hung ST; Liau MC; Chao YJ; Su CH; Yeh CS
    ACS Nano; 2013 Oct; 7(10):8516-28. PubMed ID: 24070408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ru(II) Polypyridyl Complexes Derived from Tetradentate Ancillary Ligands for Effective Photocaging.
    Li A; Turro C; Kodanko JJ
    Acc Chem Res; 2018 Jun; 51(6):1415-1421. PubMed ID: 29870227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong Influence of Ancillary Ligands Containing Benzothiazole or Benzimidazole Rings on Cytotoxicity and Photoactivation of Ru(II) Arene Complexes.
    Lari M; Martínez-Alonso M; Busto N; Manzano BR; Rodríguez AM; Acuña MI; Domínguez F; Albasanz JL; Leal JM; Espino G; García B
    Inorg Chem; 2018 Nov; 57(22):14322-14336. PubMed ID: 30379535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy.
    Reeßing F; Szymanski W
    Curr Med Chem; 2017; 24(42):4905-4950. PubMed ID: 27601187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds.
    Hongthong K; Ratanaphan A
    Curr Cancer Drug Targets; 2016; 16(7):606-17. PubMed ID: 26845433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photocontrolled DNA binding of a receptor-targeted organometallic ruthenium(II) complex.
    Barragán F; López-Senín P; Salassa L; Betanzos-Lara S; Habtemariam A; Moreno V; Sadler PJ; Marchán V
    J Am Chem Soc; 2011 Sep; 133(35):14098-108. PubMed ID: 21797210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.